Structural insight into interleukin-4Rα and interleukin-5 inhibition by nanobodies from a bispecific antibody

Weicheng Qiu; Jinguo Meng; Zhipeng Su; Wei Xie; Gaojie Song

doi:10.1002/mco2.700

MedComm ›› 2024, Vol. 5 ›› Issue (9) :e700 DOI: 10.1002/mco2.700

LETTER

Structural insight into interleukin-4Rα and interleukin-5 inhibition by nanobodies from a bispecific antibody

Author information +

History +

PDF

Cite this article

Download citation ▾

Weicheng Qiu, Jinguo Meng, Zhipeng Su, Wei Xie, Gaojie Song. Structural insight into interleukin-4Rα and interleukin-5 inhibition by nanobodies from a bispecific antibody. MedComm, 2024, 5(9): e700 DOI:10.1002/mco2.700

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Gandhi NA, Bennett BL, Graham NM, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2015; 15: 35-50.

[2]	Chikumoto A, Oishi K, Hamada K, et al. Sequential biotherapy targeting IL-5 and IL-4/13 in patients with eosinophilic asthma with sinusitis and otitis media. Biomolecules. 2022; 12: 522.

[3]	Kobe B, et al. Rapid and robust antibody Fab fragment crystallization utilizing edge-to-edge beta-sheet packing. Plos One. 2020; 15: e0232311.

[4]	Hage T, Sebald W, Reinemer P. Crystal structure of the interleukin-4/receptor α chain complex reveals a mosaic binding interface. Cell. 1999; 97: 271-281.

[5]	Le Floc’h A, Allinne J, Nagashima K, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation. Allergy. 2020; 75: 1188-1204.

RIGHTS & PERMISSIONS

2024 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.